A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD) and kidney failure globally. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces the risk of major kidney, cardiovascular and mortality outcom…
Chronic kidney disease (CKD) has become highly prevalent worldwide, with major implications for public health, including increased risk of progression to kidney failure, cardiovascular events, and mortality. Up to a decade ago, renin-angiotensin syst…
Glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) belong to a class of compounds that reduce blood glucose and energy intake by simulating actions of endogenous incretin hormone GLP-1 after it is released by the gut following food consumption.…
INTRODUCTION: The evoke/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluat…
INTRODUCTION: Although the onset and progression of diabetic microvascular complications are linked to glycemic control, various antihyperglycemic drugs with distinct treatment targets may positively impact microvascular lesions beyond their glucose-…
OBJECTIVES: In this study, the comparative bioavailability of semaglutide following the administration of oral (PO) and subcutaneous (SC) doses in healthy subjects was evaluated. The pharmacokinetics of semaglutide of these formulations at lower dose…
IMPORTANCE: Preclinical, observational, and pharmacoepidemiology evidence indicates that glucagon-like peptide 1 receptor agonists (GLP-1RAs) may reduce alcohol intake. Randomized trials are needed to determine the clinical significance of these find…
Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic disorder in reproductive-aged women, often associated with obesity and dyslipidemia. Semaglutide, a GLP-1 receptor agonist (GLP-1 RA), improves glycemic control and weight, but its effe…
INTRODUCTION: Obesity is a chronic and relapsing disease and metabolic and bariatric surgery (MBS) provides the greatest weight loss efficacy to improve obesity related complications. However, weight recurrence and suboptimal weight loss occur in som…
STUDY DESIGN: Systematic review. OBJECTIVE: The objective of this study is to: 1) systematically review Glucagon-like peptide-1 receptor agonists (GLP-1 RA) impact on spine surgery outcomes 2) review general benefits and adverse effects, and 3) discu…
STUDY DESIGN: Retrospective Cohort Study of National Database. OBJECTIVE: This study examines their effect on medical and mechanical complications within 90 days postlumbar spine surgery. SUMMARY OF BACKGROUND DATA: Patients undergoing spinal procedu…
CONTEXT: There is emerging evidence suggesting a possible association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) and non-arteritic anterior ischemic optic neuropathy (NAION). Retrospective cohort studies supporting this association…
INTRODUCTION: More than half of diabetes patients are Asians, and their tolerance to antidiabetic drugs may differ from that of non-Asians. Oral semaglutide has recently gained attention for its advantages in glycemic and body weight control. However…
The 2025 Conference on Retroviruses and Opportunistic Infections (CROI) showcased advances in understanding neuropsychiatric complications among people with HIV (PWH). This review synthesizes key findings related to central nervous system (CNS) reser…
Semaglutide has recently received conditional accelerated approval in the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with significant or advanced liver fibrosis (stage F2/F3). Phase 2 and 3 clinical trials show that s…
INTRODUCTION: Diabetes management involves using various oral hypoglycemic agents, including new glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide, tirzepatide, and liraglutide. Artificial intelligence (AI) tools such as ChatGPT (Ope…
IMPORTANCE: Semaglutide is a widely used treatment for diabetes and obesity, offering considerable cardiovascular benefit. However, its association with ocular adverse events remains uncertain. OBJECTIVE: To assess the incidence of eye disorders, dia…